Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Aconitase clusters are prone to oxidations and are among the
2024-08-01

Aconitase clusters are prone to oxidations and are among the first to undergo a change in transition state during stages of electrophilic stress rendering them inactive [31]. Aconitase activity in LETO and OLETF did not differ at T0 suggesting that the early onset of insulin resistance may not be at
-
Although many factors influence the effects of
2024-08-01

Although many factors influence the effects of medications, during recent years it has become evident that genetic factors could explain the differences between individuals in drug response. These differences are due to variants in genes encoding drug targets [8]. The challenge for pharmacogenetics
-
br Acknowledgments and Disclosures br Alzheimer s disease as
2024-08-01

Acknowledgments and Disclosures Alzheimer's disease as a synaptic pathology Alzheimer's disease (AD) is a chronic neurodegenerative MK-0752 disorder and the most common cause of dementia in the elderly. Progressive depositions of amyloid plaques and neurofibrillary tangles together with degen
-
Within the thrombus there is heterogeneity in the
2024-08-01

Within the thrombus, there is heterogeneity in the activation of Droxinostat based on the concentration gradients of soluble agonists emanating from the site of vascular injury, which has been excellently reviewed by Tomaiuolo et al.[1]. As part of the coagulation cascade, active thrombin is genera
-
BITC significantly enhanced the gene expression of the Nrf
2024-08-01

BITC significantly enhanced the gene expression of the Nrf2-dependent genes, such as NQO1 and HO-1 (Fig. 4), as well as the ALDH genes (Fig. 2). Nrf2 is a key transcriptional factor which activates the expression of the genes that contain ARE in their promoter. Nrf2 translocates to the nucleus where
-
Our findings establish a critical
2024-08-01

Our findings establish a critical link between HemAC-Lm dimeric structure and cAMP synthesis that helps in explaining how globin-A domain influences AC domain. The following possible homodimeric structure of wild type full length HemAC-Lm has been proposed to explain the role of this globin-A domain
-
In the past few years several
2024-08-01

In the past few years, several experimental findings have demonstrated a pivotal involvement of adenosine also in driving the phenotypic switch of macrophages. In particular, the stimulation of A2A and A2B receptors seems to play a critical role in switching macrophages from M1 to M2 phenotype [37,6
-
br Author contributions br Conflict of interest br Acknowled
2024-07-31

Author contributions Conflict of interest Acknowledgements This work was supported by the National Natural Science Foundation of China (81502276), Major Projects of Science and Technology of Health and Family Planning Commission of Hunan Province (A2017013), the Natural Science Foundation o
-
gsk3 inhibitor Introduction Cancer which is responsible for
2024-07-31

Introduction Cancer, which is responsible for a million deaths each year, is universally feared, and approximately 50% of newly diagnosed cases can be cured [1]. The existing cancer treatments, including surgery, chemotherapy, radiotherapy or a combination of them, are quickly losing efficacy. The
-
To maintain ATP levels postmortem
2024-07-31

To maintain ATP levels, postmortem muscle mobilizes its glycogen reserves to yield XMD17-109 6-phsphate that proceeds through glycolysis. Glycogen degradation was affected by the interaction between treatment and time (Pinitiation of the experiment. We expected that if myosin ATPase is limiting, the
-
br ASK in Huntington s
2024-07-31

ASK1 in Huntington's disease and other polyglutamine diseases The polyglutamine (polyQ) diseases are a group of inherited neurodegenerative disorders caused by the expansion of cytosine-adenine-guanine (CAG) trinucleotide repeats in the coding regions of specific genes, leading to the production
-
The functions of HMGN protein are modulated by
2024-07-31

The functions of HMGN1 protein are modulated by various post-translational modifications, including phosphorylation , , , acetylation , and glycosylation . Phosphorylation in HMGN1 may influence its binding affinity to DNA or nucleosome-associated proteins and affect the sub-cellular localization an
-
Incubation of the aortic segments of
2024-07-31

Incubation of the aortic segments of rats with indomethacin significantly decreased the vasoconstrictor response to Phe but only in HgCl2-treated group (Fig. 9A,B), as indicated by dAUC values (Fig. 9E). Co-treatment with losartan once again proved to be effective and prevented the increased partici
-
Finally microRNAs miRNA seem to play
2024-07-31

Finally, microRNAs (miRNA) seem to play an important role in AR signaling in BC. Some authors have described a differential LJI308 synthesis of miRNAs in AR-positive BCs compared to AR-negative ones. VEGF and mTOR pathways were also reported as implicated in miRNA dysregulation, suggesting a common
-
The major phase trial NCT
2024-07-31

The major phase 2 trial (NCT01343966) enrolled 431 participants with mild to moderate AD who received either low-dose SC crenezumab 300 mg or placebo biweekly (n = 184) or high-dose intravenous crenezumab 15 mg/kg or placebo every 4 weeks (n = 247) for 68 weeks 38, 40. No significant treatment benef
16141 records 118/1077 page Previous Next First page 上5页 116117118119120 下5页 Last page